Tag: Cardiomyopathy

Affecting approximately 1 in 500 people, hypertrophic cardiomyopathy (HCM) is a genetic heart condition that causes the heart muscle to thicken. Mavacamten (brand name Camzyos) is the new drug for hypertrophic cardiomyopathy, specifically for the obstructive type (oHCM).

Tacrolimus-induced cardiotoxicity is a rare, but serious, adverse effect, with case reports describing hypertrophic cardiomyopathy in transplant recipients. While primarily used to prevent organ rejection, clinicians must consider the potential for tacrolimus to cause heart problems and monitor patients accordingly.

According to recent studies, the risk of hydroxychloroquine-induced retinopathy can be as high as 20% after 20 years of use. While a vital treatment for autoimmune conditions like lupus and rheumatoid arthritis, understanding **what is the major toxic effect of hydroxychloroquine?** is crucial for long-term patient safety.

Recurrent pericarditis can affect up to 23% of patients, even with standard medical therapy. For those who do not respond to conventional treatments like NSAIDs and colchicine, a newer, targeted approach is necessary, and this is where the medication anakinra is used for pericarditis.

While tacrolimus is a highly effective immunosuppressant for organ transplant recipients, a small but clinically significant number of patients have experienced serious cardiovascular side effects. So, **can tacrolimus affect your heart**? Evidence confirms it can, necessitating vigilant monitoring for these rare but potentially serious cardiac risks.